Evidence map›Paper›PMID 29089450›Full record

ArticleScience signaling2017

MARK3-mediated phosphorylation of ARHGEF2 couples microtubules to the actin cytoskeleton to establish cell polarity.

María-José Sandí, Christopher B Marshall, Marc Balan, Étienne Coyaud, Ming Zhou, Daniel M Monson, Noboru Ishiyama, Arun A Chandrakumar, José La Rose, Amber L Couzens and 6 more

Open access · greenAbstract read
In one paragraph

Article in Science signaling, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. TEX38 localizes ZDHHC19 to the plasma membrane and regulates sperm head morphogenesis in mice.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 3 countries.

María-José SandíPrincess Margaret Cancer Centre, University Health Network, 101 College Street, Princess Margaret Cancer Research Tower, Toronto, Ontario M5G 1L7, Canada.ORCID http://orcid.org/0000-0002-4782-3800
Christopher B MarshallPrincess Margaret Cancer Centre, University Health Network, 101 College Street, Princess Margaret Cancer Research Tower, Toronto, Ontario M5G 1L7, Canada.
Marc BalanPrincess Margaret Cancer Centre, University Health Network, 101 College Street, Princess Margaret Cancer Research Tower, Toronto, Ontario M5G 1L7, Canada.ORCID http://orcid.org/0000-0002-7893-2786
Étienne CoyaudPrincess Margaret Cancer Centre, University Health Network, 101 College Street, Princess Margaret Cancer Research Tower, Toronto, Ontario M5G 1L7, Canada.
Ming ZhouCenter for Cancer Research, National Cancer Institute at Frederick, P.O. Box B, Frederick, MD 21702, USA.
Daniel M MonsonCenter for Cancer Research, National Cancer Institute at Frederick, P.O. Box B, Frederick, MD 21702, USA.
Noboru IshiyamaPrincess Margaret Cancer Centre, University Health Network, 101 College Street, Princess Margaret Cancer Research Tower, Toronto, Ontario M5G 1L7, Canada.
Arun A ChandrakumarPrincess Margaret Cancer Centre, University Health Network, 101 College Street, Princess Margaret Cancer Research Tower, Toronto, Ontario M5G 1L7, Canada.
José La RosePrincess Margaret Cancer Centre, University Health Network, 101 College Street, Princess Margaret Cancer Research Tower, Toronto, Ontario M5G 1L7, Canada.ORCID http://orcid.org/0000-0001-6024-3125
Amber L CouzensLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada.ORCID http://orcid.org/0000-0003-0057-6686
Anne-Claude GingrasLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada.ORCID http://orcid.org/0000-0002-6090-4437
Brian RaughtPrincess Margaret Cancer Centre, University Health Network, 101 College Street, Princess Margaret Cancer Research Tower, Toronto, Ontario M5G 1L7, Canada.
Wei XuDalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Mitsuhiko IkuraPrincess Margaret Cancer Centre, University Health Network, 101 College Street, Princess Margaret Cancer Research Tower, Toronto, Ontario M5G 1L7, Canada.
Deborah K MorrisonCenter for Cancer Research, National Cancer Institute at Frederick, P.O. Box B, Frederick, MD 21702, USA.ORCID http://orcid.org/0000-0002-1928-1987
Robert RottapelPrincess Margaret Cancer Centre, University Health Network, 101 College Street, Princess Margaret Cancer Research Tower, Toronto, Ontario M5G 1L7, Canada. rottapel@uhnresearch.ca.ORCID http://orcid.org/0000-0002-6024-5558
Princess Margaret Cancer Centre · CAUniversity of Toronto · CAFrederick National Laboratory for Cancer Research · USMount Sinai Hospital · CASt. Michael's Hospital · CA

Funding

Regulation of Ras-Dependent Signal Transduction PathwaysZIABC010329 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MORRISON, DEBORAH · 2009 to 2025
$16.1M
Role of Protein Scaffolds in RTKRas-dependent Signal TransductionZIABC011107 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MORRISON, DEBORAH · 2009 to 2025
$7.3M
Intramural NIH HHS ZIA BC010329
6 · The paper itself

Abstract

The PAR-1-MARK pathway controls cell polarity through the phosphorylation of microtubule-associated proteins. Rho-Rac guanine nucleotide exchange factor 2 (ARHGEF2), which activates Ras homolog family member A (RHOA), is anchored to the microtubule network and sequestered in an inhibited state through binding to dynein light chain Tctex-1 type 1 (DYNLT1). We showed in mammalian cells that liver kinase B1 (LKB1) activated the microtubule affinity-regulating kinase 3 (MARK3), which in turn phosphorylated ARHGEF2 at Ser

Indexed as

Actin CytoskeletonAMP-Activated Protein Kinase KinasesAnimalsCell PolarityChlorocebus aethiopsCOS CellsDyneinsFocal AdhesionsHEK293 CellsHumansMicrotubulesPhosphorylationProtein Phosphatase 2Protein Serine-Threonine KinasesrhoA GTP-Binding ProteinRho Guanine Nucleotide Exchange FactorsAMP-Activated Protein Kinase KinasesARHGEF2 protein, humanDyneinsDYNLT1 protein, humanMARK3 protein, humanProtein Phosphatase 2Protein Serine-Threonine KinasesrhoA GTP-Binding ProteinRHOA protein, humanRho Guanine Nucleotide Exchange FactorsSerineSTK11 protein, human

Identifiers

PMID29089450
PMCPMC6504561
OpenAlexW2766339762

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.